X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1918) 1918
Publication (83) 83
Book Review (31) 31
Book Chapter (6) 6
Dissertation (5) 5
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1030) 1030
humans (816) 816
sglt2 inhibitor (737) 737
type 2 diabetes (737) 737
diabetes (720) 720
glucose (636) 636
diabetes mellitus, type 2 - drug therapy (591) 591
sglt2 inhibitors (578) 578
dapagliflozin (561) 561
endocrinology & metabolism (538) 538
double-blind (445) 445
sodium-glucose transporter 2 - antagonists & inhibitors (444) 444
male (442) 442
sglt2 (436) 436
hypoglycemic agents - therapeutic use (423) 423
diabetes mellitus (365) 365
pharmacology & pharmacy (358) 358
dextrose (356) 356
female (343) 343
empagliflozin (333) 333
canagliflozin (323) 323
animals (307) 307
insulin (298) 298
glucosides - therapeutic use (294) 294
middle aged (284) 284
metformin (274) 274
sodium (262) 262
type 2 diabetes mellitus (260) 260
hyperglycemia (254) 254
glycemic control (253) 253
safety (237) 237
hypoglycemic agents - adverse effects (214) 214
type-2 diabetes-mellitus (210) 210
analysis (209) 209
adult (204) 204
mellitus (204) 204
hypoglycemic agents - pharmacology (203) 203
inadequate glycemic control (198) 198
sodium-glucose transporter 2 - metabolism (198) 198
care and treatment (194) 194
treatment outcome (194) 194
benzhydryl compounds - therapeutic use (193) 193
diabetes mellitus, type 2 - blood (191) 191
internal medicine (189) 189
efficacy (188) 188
aged (183) 183
drug therapy (180) 180
hypoglycemic agents (180) 180
glucosides - pharmacology (173) 173
blood glucose - drug effects (170) 170
clinical trials (170) 170
blood glucose - metabolism (169) 169
blood pressure (165) 165
diabetes therapy (159) 159
glucosides - adverse effects (158) 158
hypoglycemic agents - administration & dosage (153) 153
medicine & public health (153) 153
blood-pressure (138) 138
diabetes mellitus, type 2 - metabolism (138) 138
heart failure (138) 138
add-on (137) 137
double-blind method (134) 134
rats (134) 134
kidney (133) 133
glucosides - administration & dosage (130) 130
hypoglycemia (129) 129
medicine, general & internal (126) 126
body weight (125) 125
risk factors (125) 125
diabetes mellitus, type 2 - complications (122) 122
glucose metabolism (118) 118
inhibitors (118) 118
inhibitor (116) 116
patients (116) 116
glucose - metabolism (114) 114
drug therapy, combination (113) 113
placebo-controlled trial (113) 113
cardiac & cardiovascular systems (111) 111
benzhydryl compounds - pharmacology (109) 109
mortality (109) 109
endocrinology (107) 107
pharmacokinetics (107) 107
review (107) 107
dose-response relationship, drug (105) 105
research (104) 104
benzhydryl compounds - adverse effects (103) 103
insulin resistance (103) 103
japanese patients (103) 103
mice (103) 103
metabolism (102) 102
add-on therapy (101) 101
kidney - metabolism (100) 100
cardiovascular disease (96) 96
glycosylated hemoglobin (95) 95
glucose transporter (94) 94
monotherapy (92) 92
risk (92) 92
benzhydryl compounds - administration & dosage (90) 90
hemoglobin (88) 88
type-2 (88) 88
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1778) 1778
French (32) 32
Japanese (32) 32
German (29) 29
Spanish (20) 20
Czech (9) 9
Russian (8) 8
Chinese (7) 7
Korean (4) 4
Slovak (4) 4
Polish (3) 3
Arabic (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic Research, ISSN 0289-8020, 2017, Volume 38, Issue 4, pp. 409 - 412
Journal Article
Therapeutic Research, ISSN 0289-8020, 2016, Volume 37, Issue 1, pp. 31 - 36
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2012, Volume 14, Issue 1, pp. 5 - 14
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2014, Volume 16, Issue 2, pp. 124 - 136
AimsDapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and... 
type 2 diabetes | insulin | inhibitor | SGLT2 | randomized trial | glycaemic control | renal glucose handling | Type 2 diabetes | Randomized trial | Renal glucose handling | Insulin | SGLT2 inhibitor | Glycaemic control | METFORMIN | SELECTIVE SGLT2 INHIBITOR | ADD-ON | MELLITUS | INADEQUATE GLYCEMIC CONTROL | BODY-WEIGHT | PHARMACOKINETICS | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | WEIGHT-GAIN | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Weight Loss - drug effects | Genital Diseases, Female - chemically induced | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Aged, 80 and over | Adult | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Genital Diseases, Male - chemically induced | Insulin - administration & dosage | Treatment Outcome | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Complications and side effects | Glucose metabolism | Care and treatment | Analysis | Urinary tract infections | Glucose | Dextrose | Infections | Diabetes
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2015, Volume 17, Issue 10, pp. 936 - 948
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2014, Volume 16, Issue 10, pp. 984 - 993
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2018, Volume 72, Issue 15, pp. 1845 - 1855
Patients with type 2 diabetes mellitus have an increased risk for the development of cardiac and other vascular events, heart failure (HF), and decline in... 
heart failure | renal function | diabetes | SGLT2 inhibitor | KIDNEY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | DAPAGLIFLOZIN | SGLT2 INHIBITORS | HEART-FAILURE | RISK | DEATH | ESTABLISHED CARDIOVASCULAR-DISEASE | PHARMACOKINETICS | OUTCOMES | EMPAGLIFLOZIN
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 12/2019, Volume 18, Issue 1, pp. 1 - 4
Abstract Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart... 
Heart failure | Dapagliflozin | SGLT2 inhibitors
Journal Article
Tetrahedron, ISSN 0040-4020, 09/2018, Volume 74, Issue 39, pp. 5700 - 5708
A new method for the diastereoselective synthesis of enantiomerically pure ertugliflozin was developed. The crucial step involves an aldol condensation between... 
l-arabinose | Dihydroxylation | Ertugliflozin | Aldol condensation | SGLT2 inhibitors | L-arabinose | ROUTE | SGLT2 INHIBITOR | CHEMISTRY, ORGANIC | Sugars | Monosaccharides
Journal Article
DIABETES CARE, ISSN 0149-5992, 09/2011, Volume 34, Issue 9, pp. 2015 - 2022
OBJECTIVE-Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective... 
INSULIN | STATEMENT | EUROPEAN-ASSOCIATION | HYPERGLYCEMIA | MONOTHERAPY | MANAGEMENT | CONSENSUS ALGORITHM | SGLT2 INHIBITOR | INITIATION | ENDOCRINOLOGY & METABOLISM | ADJUSTMENT
Journal Article
Circulation Journal, ISSN 1346-9843, 2018
Background:This study aimed to investigate the effect and safety of sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in patients with drug-refractory heart... 
Heart failure | Diabetes | SGLT2 inhibitors
Journal Article
Circulation, ISSN 0009-7322, 02/2014, Volume 129, Issue 5, pp. 587 - 597
Journal Article
Journal Article